Shots:

• The P-III PROVENT & TACKLE trial evaluates AZD7442 (IM) vs PBO in a ratio (2:1) & (1:1) in 5197 & 903 patients with COVID-19
• In the PROVENT trial, AZD7442 (300mg) showed an 83% reduction in risk of developing symptomatic COVID-19, 75% of patients had co-morbidities. In an exploratory analysis of a TACKLE outpatient treatment trial, AZD7442 (600mg) showed an 88% reduction in risk of developing sev. COVID-19 or death, 90% of patients were at high risk of progression to sev. COVID-19 incl. co-morbidities
• Additionally, both trials showed a robust efficacy from a one-time IM dose of an LAAB combination. The therapy was well tolerated with no new safety issues in 6mos. analysis of PROVENT trial

to­Ref: AstraZeneca | Image: The Scientist Magazine